SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YEEHAW CANDIDATES
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Galirayo who wrote (19694)10/30/2006 8:57:27 AM
From: ACAN  Read Replies (3) of 23958
 
Ray; [PPHM}

Positive Results From Peregrine's Bavituximab Phase Ia HCV Trial Presented At AASLD Meeting
Monday October 30, 8:00 am ET
-First-in-Class Targeted Immunotherapeutic Agent Appears Safe and Well Tolerated at All Doses Tested in Single Dose Trial in Patients With Chronic HCV infection-
-Final Study Data Confirm Encouraging Signs of Anti-Viral Activity in Patients Who Had Failed Traditional Anti-Viral Therapies-
- Enrollment in Phase Ib Repeat Dose HCV Trial Recently Completed and Planning for Additional Trials Underway-

Allan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News